Oct 27, 2024 · Impact of MitraClip on Hospitalization Rates in Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation: Insights From RESHAPE-HF2

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

Oct 17, 2024 · One of the major themes of this year’s meeting is intervening earlier to prevent disease, including with TAVI in aortic stenosis.

Aug 28, 2024 · Tirzepatide, when used for weight loss under the brand name Zepbound, is now more affordable thanks to a self-pay option created by the manufacturer, Lilly. The discount is available through the company’s own online pharmacy. The drug, an agonist of both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, has previously been sold ...

Nov 8, 2024 · For once, cardiologists find good news in the US Centers for Medicare & Medicaid Services (CMS) annual Hospital Outpatient Prospective Payment System (HOPPS) final rule: in 2025 the payment rate for coronary computed tomography angiography (CCTA) will double. Cardiac imagers have long lamented the fact that low reimbursement for CCTA has been a major hurdle limiting access to the technology ...

Oct 10, 2024 · The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Oct 30, 2024 · WASHINGTON, DC—As a guide for deciding whether to revascularize patients with intermediate coronary stenoses, quantitative flow ratio (QFR) isn’t able to match fractional flow reserve (FFR) in terms of 12-month clinical outcomes, data from the large, randomized, FAVOR III Europe trial show. The findings call into question current guidelines for functional assessment, said Birgitte ...

Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released by Eli Lilly on Wednesday. Tirzepatide (Zepbound; Eli Lilly) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, while semaglutide (Wegovy; Novo Nordisk) is ...

Oct 28, 2024 · (UPDATED) While discussions about the lack of a mortality effect will continue, some say the findings may be enough to change guidelines.

Mar 6, 2024 · The Micra VR leadless pacemaker (Medtronic) continues to have a good safety and efficacy profile through the 5-year mark, according to real-world registry data. Rates of major complications and revisions were both under 5%, and no patients required device removal for infection. Moreover, as researchers led by Mikhael El-Chami, MD (Emory University, Atlanta, GA), report in a study published ...